Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

clinical stage biotechnology

  • Home
  •  
  • clinical stage biotechnology



  • Most Read
  • Latest Comments
  • PYC Therapeutics receives Orphan Drug Designation for ADOA treatment
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • PYC Therapeutics receives Orphan Drug Designation for ADOA treatment
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • PYC Therapeutics receives Orphan Drug Designation for ADOA treatment
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • PYC Therapeutics receives Orphan Drug Designation for ADOA treatment
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • PYC Therapeutics receives Orphan Drug Designation for ADOA treatment
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • PYC Therapeutics receives Orphan Drug Designation for ADOA treatment
    PYC Therapeutics receives Orphan Drug Designation for ADOA treatment
    • News

  • All eyes on PYC as it doses first patient for eye disease trial
    All eyes on PYC as it doses first patient for eye disease trial
    • News

  • PYC gets FDA clearance to kick off human trials for its investigative drug combatting blindness
    PYC gets FDA clearance to kick off human trials for its investigative drug combatting blindness
    • News

  • PYC Therapeutics receives Orphan Drug Designation for ADOA treatment
    • News

    PYC Therapeutics receives Orphan Drug Designation for ADOA treatment

    PYC Therapeutics (ASX: PYC), a clinical-stage biotechnology company, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation (ODD) to its investigational drug candidate, PYC-001. This precision therapy is designed to treat Autosomal Dominant Optic Atrophy (ADOA), a rare and progressive blinding eye disease. This designation is expected

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.